NCT04172259View on ClinicalTrials.gov

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

January 10, 2019

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2026

Conditions
Breast CancerNeoadjuvant Chemotherapy
Interventions
DRUG

Doxorubicin liposome

PLD

DRUG

Cyclophosphamide

CTX

DRUG

Trastuzumab

H

DRUG

Docetaxel

DOC

DRUG

Epirubicin

EPI

DRUG

Pertuzumab

P

DRUG

Paclitaxel

paclitaxel (PTX) 175 mg/m2 every 3 weeks or paclitaxel (PTX) 80 mg/m2 every week

DRUG

Paclitaxel-albumin

albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

lead

Sun Yat-sen University

OTHER